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ABSTRACT
Objective: Recent studies performed in mice revealed that the neuropeptide 26RFa regulates 
glucose homeostasis by acting as an incretin, and by increasing insulin sensitivity. However, 
in human, an association between 26RFa and the regulation of glucose homeostasis is poorly 
documented.  In this study, we have thus investigated in detail the distribution of 26RFa and 
its receptor, GPR103, in the gut and the pancreas, and determined the response of this 
peptidergic system to an oral glucose challenge in obese patients. 
Design and Methods: Distribution of 26RFa and GPR103 was examined by 
immunohistochemistry using gut and pancreas tissue sections. Circulating 26RFa was 
determined using a specific radioimmunoassay in plasma samples collected during an oral 
glucose tolerance test.
Results: 26RFa and GPR103 are present all along the gut but are more abundant in the 
stomach and duodenum. In the stomach, the peptide and its receptor are highly expressed in 
the gastric glands, whereas in the duodenum, ileum and colon they are present in the 
enterocytes and the goblet cells. In the pancreatic islets, the 26RFa/GPR103 system is mostly 
present in the β cells. During an oral glucose tolerance test, plasma 26RFa profile is different 
between obese patients and healthy volunteers, and we found strong positive correlations 
between 26RFa blood levels and the BMI, and with various parameters of insulin secretion 
and insulin resistance. 
Conclusion: the present data suggest an involvement of the 26RFa/GPR103 peptidergic 
system in the control of human glucose homeostasis.
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INTRODUCTION
Glucose homeostasis is a crucial parameter to maintain normal body function. Control of 
blood glucose levels is ensured by a highly sophisticated network of various hormones 
released by the pancreas, intestine, liver, adipose and muscle tissue, and the brain (1). In 
particular, accumulating evidence obtained during the last decade support the peripheral role 
of hypothalamic neuropeptides controlling feeding behaviour such as neuropeptide Y (NPY), 
orexins, ghrelin, corticotropin-releasing factor (CRF) or apelin, in the regulation of glucose 
homeostasis (2-6), coining the new concept that hypothalamic neuropeptides may serve as a 
link between energy and glucose homeostasis, and identifying them therefore as potential 
therapeutic targets for the treatment of diabetes and obesity (7,8).
26RFa (also referred to as QRFP) is a hypothalamic neuropeptide discovered concurrently 
by us and others (9-11). Subsequently, 26RFa has been characterized in all the vertebrate 
phyla including human (12, 13), and identified as the cognate ligand of the human orphan G 
protein-coupled receptor, GPR103 (10-12, 14). Neuroanatomical observations have revealed 
that 26RFa- and GPR103-expressing neurons are primarily localized in hypothalamic nuclei 
involved in the control of feeding behaviour (9, 10, 14-16). Indeed, i.c.v. administration of 
26RFa stimulates food intake (9, 14, 17, 18), and the neuropeptide exerts its orexigenic 
activity by modulating the NPY/POMC system in the arcuate nucleus (Arc) (18). 26RFa also 
stimulates food intake in birds (19) and fish (20), indicating that 26RFa plays a crucial role in 
the central regulation of body weight and energy homeostasis in all vertebrates. Consistent 
with this notion, recent data obtained from 26RFa-deficient mice revealed that the knock-out 
mice are lean and hypophagic, and that, under a high fat diet, the 26RFa-/- mice show a lower 
weight gain than the wild-type animals (21). In agreement with this latter observation, a more 
sustained orexigenic activity of 26RFa has been reported in obese rodents (17, 22), and 
expression of prepro26RFa mRNA is up-regulated in the hypothalamus of genetically obese 
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ob/ob and db/db mice (14) and in rodents submitted to a high fat diet (17, 22). Altogether, 
these findings support the notion that 26RFa could play a role in the development and 
maintenance of the obese status (13).
Recently, an implication of the 26RFa/GPR103 neuropeptidergic system in the control of 
glucose homeostasis has been reported. It was found that 26RFa and GPR103 are expressed 
by the pancreatic islets as well as by various insulin-secreting cell lines (23, 24) and that the 
neuropeptide prevents cell death and apoptosis of β cell lines and isolated pancreatic islets 
(23). It was also shown that 26RFa is abundantly expressed all along the gut and that i.p. 
administration of the neuropeptide attenuates glucose-induced hyperglycemia by increasing 
plasma insulin via a direct insulinotropic effect on the pancreatic β cells, and by increasing 
insulin sensitivity (24). Finally, it was reported that an oral glucose challenge induces a 
massive secretion of 26RFa by the gut into the blood, strongly suggesting that this 
neuropeptide regulates glycemia by acting as an incretin (24).
In human, an association between the 26RFa/GPR103 system and the regulation of glucose 
homeostasis is far more limited. This observation prompted us to investigate in detail the 
distribution of 26RFa and its receptor all along the gastrointestinal tract and in the pancreas, 
and determined the response of this peptidergic system to an oral glucose challenge in obese 
patients vs healthy volunteers.
 . 
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MATERIALS AND METHODS
Immunohistochemical procedure
Deparaffinized sections (15-µm thick) of human pancreas, stomach, duodenum, ileum and 
colon were used for the immunohistochemical study. Human tissue sections were obtained 
from our Department of Pathology at the University Hospital of Rouen. All of the tissue 
procurement protocols were approved by the relevant institutional committees (University of 
Rouen) and were undertaken under informed consent of each patient and all of the 
participants. Tissue sections were incubated for 1 h at room temperature with either rabbit 
polyclonal antibodies against 26RFa (25) diluted 1:400, or GPR103 (#NLS1922; Novus 
Biologicals, Littletown, CO) diluted 1:100, or mouse monoclonal antibodies against insulin 
(Sigma-Aldrich, Saint-Quentin Fallavier, France) diluted 1:1000, or goat polyclonal 
antisomatostatin (Santa Cruz Biotechnology, Dallas, TX) diluted 1:500, or mouse monoclonal 
antiglucagon (Sigma-Aldrich) diluted 1:400. The sections were incubated with a streptavidin-
biotin-peroxydase complex (Dako Corporation, Carpinteria, CA), and the enzymatic activity 
was revealed with diaminobenzidine. The slices were then counterstained with hematoxylin. 
Observations were made under a Nikon E 600 light microscope. 
For colocalization studies, the following primary antibodies were used: rabbit polyclonal 
anti-human 26RFa (25) and mouse monoclonal anti-insulin (1:400) (Sigma-Aldrich). Alexa-
conjugated antibodies (Invitrogen Life Technologies) including donkey antirabbit (1:100) 
(DAR-488) and goat antimouse (1:400) (GAM-594) were used as secondary antibodies. 
Sections were counterstained with 1 μg/mL 4′,6-diamino-2-phenylindole (Sigma-Aldrich) in 
PBS for 90 seconds. Tissue sections were examined with a Leica SP2 upright confocal laser 
scanning microscope (DMRAX-UV) equipped with the Acousto-Optico Beam Splitter system 
(Leica). The specificity of the immunoreactions was controlled by (1) substitution of the 
primary antibodies with Tris buffer saline (TBS; pH 7.4) and (2) preincubation of the primary 
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antisera with the corresponding synthetic peptides (10-6 M), with the exception of GPR103 
whose antigen sequence was unknown. In both cases, no immunoreaction was observed. 
Oral glucose tolerance test 
Eight obese patients (BMI>40 kg/m2), who performed usual examinations before bariatric 
surgery, were recruited. Healthy controls (C) underwent standard endocrine tests to exclude 
any metabolic abnormalities. The nine healthy volunteers had already been recruited for a 
previous study (26). All of the subjects included in the study gave a written informed consent 
according to our Ethical Committee instructions, and the study was approved by the Ethical 
Committee of Haute-Normandie (CCPPRB-HN; 26). The obese patients and the healthy 
volunteers underwent a 75-g oral glucose tolerance test (OGTT) after a 12-h fasting period. 
Plasma 26RFa, glucose and insulin concentrations were measured in fasting blood samples 
obtained at 0, 30, 60, and 120 min after oral glucose loading.
Human plasma assays 
Plasma 26RFa levels were measured using a specific radioimmunoassay (RIA) set up in the 
laboratory that has been previously described in detail (27). For the RIA procedure, each 
sample was diluted (1:1) in a solution of water/TFA (99.9:0.1; v/v) and pumped at a flow rate 
of 1.5 ml/min through one Sep-Pak C18 cartridge. Bound material was eluted with 
acetonitrile/water/TFA (50:49.9:0.1; v/v/v) and acetonitrile was evaporated under reduced 
pressure. Finally, the dried extracts were resuspended in the buffer assay.
Blood glucose levels were measured using a glucose oxidase activity test (LX20 Beckman 
Coulter, Villepinte, France) and plasma insulin was quantified using an Elecys for automated 
insulin Assay (COBAS 6000CE, Roche Diagnostics, Meylan, France).
Usual insulin resistance and insulin secretion indices were calculated at fasting levels and 
during the oral glucose tolerance test: 
Page 6 of 36Accepted Manuscript published as EC-19-0247.R1. Accepted for publication: 12-Jun-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/02/2019 06:40:55AM
via free access
Ve
rs
io
n 
pr
ep
rin
t
Comment citer ce document :
Prévost, G. (Auteur de correspondance), Picot, M., Le Solliec, M.-A., Arabo, A., Berrahmoune,
H., El Mehdi, M., Cherifi, S., Benani, A., Nédélec, E., Gobet, F., Brunel, V., Leprince, J.,
Lefebvre, H., Anouar, Y., Chartrel, N. (2019). The neuropeptide 26RFa in the human gut and
pancreas: potential involvement in glucose homeostasis. Endocrine Connections, 8 (7), 941-951. , DOI : 10.1530/ec-19-0247
7
- Homeostasis Model Assessment of Insulin Resistance, HOMA-R index,
[(fasting glucose (mmol/L) x fasting insulin (U/mL)] / 22.5 (28).
- Homeostasis Model Assessment of insulin secretion, Homa-β: [20 X fasting insulin 
(U/mL)] / [(fasting glucose (mmol/L)-3.5].
- Index insulinogenic 
(Insulin 30'-Insulin 0)/(Glucose 30'-Glucose 0), units (U/mL) for insulin, mmol/l for glucose 
(29).
Statistical analysis 
Statistical analysis was performed with Statistica (5th version). A Mann Whitney test or 
ANOVA for repeated measures was used for comparisons between the two groups. A post-
hoc comparison using Tukey HSD was applied according to ANOVA results. Statistical 
significance was considered for an  risk of 5%. 
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RESULTS
Distribution of 26RFa- and GPR103-like immunoreactivity in the gastrointestinal tract
In the antral part of the stomach, we found that the gastric glands were strongly labeled with 
the 26RFa antibodies (Fig. 1A, B). At low magnification, it seemed that 26RFa-LI was 
concentrated in cells of the isthmus and the neck whereas the surface epithelium cells of the 
gastric pit and the base of the gland were not immunostained (Fig. 1A, B). However, higher 
magnification revealed that surface epithelium cells contained 26RFa-LI at their basal pole 
whereas the mucus granules located at the apical pole of the cells were devoid of 
immunolabeling (Fig. 1C). Transversal section of a gastric gland at the neck level indicated 
that the 26RFa-positive cells are large and exhibit a round shape identifying them as parietal 
cells whereas the unlabeled cells are smaller and thus probably correspond to chief cells (Fig. 
1D). Preincubation of the 26RFa antibodies with synthetic human 26RFa (10-6 M) resulted in 
a total loss of the immunostaining in the gastric glands (Fig. 1E). Similarly, stomach slices on 
which the 26RFa antibodies were substituted with Tris buffer were totally devoid of labeling 
(Fig. 1F).
The localization and distribution of the 26RFa receptor, GPR103, in stomach slices was 
very similar to that of 26RFa, with the presence of abundant GPR103-like immunoreactivity 
(LI) in the gastric glands (Fig. 2A). Higher magnification photomicrographs revealed that, in 
the surface epithelium cells, GPR103-LI was concentrated in the basal pole of the cells 
whereas the apical pole containing the mucus granules was unstained, as observed for 26RFa 
(Fig. 2B, C). Similarly, at the neck level of the gland, it appears that the parietal cells 
(according to their volume and shape) expressed the 26RFa receptor whereas the chief cells 
did not (Fig. 2D). Longitudinal (Fig. 2E) or transversal sections (Fig. 2F) of gastric glands 
revealed that substitution of the GPR103 antibodies wit+h Tris buffer results in a total loss of 
the GPR103 immunolabeling.
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In the duodenum, 26RFa-LI was detected in most of the enterocytes and goblet cells of a 
number of villosities (Fig. 3A). However, we also found that other villosities were devoid of 
26RFa immunolabeling (Fig. 3B). At a higher magnification, it clearly appears that, in some 
villosities, all of the enterocytes expressed 26RFa whereas, in the adjacent villosity, the 
enterocytes were totally unstained (Fig. 3C). Figure 3D illustrates the strong 26RFa 
immunolabeling exhibited by some enterocytes and goblet cells of the duodenum. 
A low magnification of duodenal villosities clearly shows that the number of enterocytes 
and goblet cells expressing the 26RFa receptor is more restricted than for 26RFa 
immunostaining (Fig. 3E). At a higher magnification, it appears that, in some cases, GPR103 
immunostaing was concentrated in the basal pole of the enterocytes and goblet cells (Fig. 3F, 
G) whereas, in other cases, GPR103 labeling was homogeneously distributed in the cytoplasm 
of the cells (Fig. 3H). 
In the ileum, the distribution of 26RFa-LI was very similar to that observed in the 
duodenum, with an immunolabeling in the enterocytes and goblet cells (Fig. 4A). However, it 
is to note that the number of 26RFa-labeled cells in the ileum was much lower than in the 
duodenum (Fig. 4A, B). We also found GPR103 immunostaining in some enterocytes and 
goblet cells of the ileum, but the number of cells expressing the 26RFa receptor was low (Fig. 
4C). However, when the cells were labeled with the GPR103 antibodies, the immunostaining 
was intense as illustrated by these goblet cells in figure 4D.
In the colon, low magnification of villosities suggested a lack of 26RFa immunostaining 
(Fig. 4E). However, at a higher magnification, it appears that, in some villosities, enterocytes 
and goblet cells exhibited a low immunolabeling (Fig. 4E). The 26RFa receptor showed a 
general distribution, in the colon, closely related to that observed in the ileum with a low 
number of enterocytes and goblet cells strongly labeled with the GPR103 antibodies (Fig. 4G, 
H).
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Distribution of 26RFa- and GPR103-like immunoreactivity in the pancreatic islets
Treatment of human prancreas sections with the 26RFa antibodies revealed that the 
neuropeptide was present in the endocrine islets (Fig. 5A). In contrast, the exocrine tissue was 
virtually devoid of 26RFa- LI (Fig. 5A). A higher magnification showed that almost all the 
cells of the islet were strongly labeled with the 26RFa antibodies (Fig. 5B). Similarly, we 
found an intense GPR103-immunostaining in the human pancreatic islets (Fig. 5C). However, 
a high magnification of the islets revealed that some islet cells were strongly labeled with the 
26RFa receptor antibodies whereas others were devoid of immunostaining (Fig. 5D). Figures 
5E and F revealed that preincubation of the 26RFa antibodies with synthetic human 26RFa 
(10-6 M) resulted in a total loss of the immunostaining in the pancreatic islets. Similarly, 
pancreas slices on which the GPR103 antibodies were substituted with Tris buffer were totally 
devoid of labeling in the islets (Fig. 5G, H).
In addition, treatment of consecutive sections with the 26RFa antibodies and insulin 
antibodies revealed that the histological distribution of 26RFa-LI was similar to that of insulin 
(Fig. 6A, B). Supporting this observation, a double immunolabeling experiment with 26RFa 
and insulin antibodies showed a colocalization of the neuropeptide and the hormone in most 
of the pancreatic islet cells (Fig. 6C). However, it is to note that some cells were only labeled 
with the 26RFa antibodies whereas others only exhibited insulin-LI (Fig. 6C). Consecutive 
pancreas sections were also treated with the 26RFa antibodies and glucagon antibodies, and 
suggest that in some cases glucagon cells express the neuropeptide (Fig. 6D, E). Similarly, 
treatment of consecutive sections with the 26RFa antibodies and somatostatin antibodies 
revealed that some somatostatin-producing cells expressed 26RFa (Fig. 6F, G).
Concurrently, treatment of consecutive sections with the GPR103 antibodies and insulin 
antibodies showed that the histological distribution of GPR103-LI was closely related to that 
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of insulin (Fig. 7A, B). Consecutive pancreas sections were also treated with either the 
GPR103 antibodies or glucagon antibodies and the observations revealed that some glucagon-
positive cells also expressed the 26RFa receptor (Fig. 7C, D). Similarly, treatment of 
consecutive sections with the GPR103 antibodies and somatostatin antibodies suggested that a 
few somatostatin-producing cells expressed the 26RFa receptor (Fig. 7E, F).
Oral glucose tolerance test in human
An oral glucose tolerance test was performed on 8 obese patients and 9 healthy volunteers. 
Age was not significantly different between the two groups (43±3.7 for obese patients vs 
35.3±3.7 years for the healthy volunteers). By contrast and as expected, BMI and insulin 
fasting levels were significantly higher in the obese patients as compared to controls (BMI: 
46.4 ± 1.9 vs 21.1 ± 0.7 kg/m2, p<0.0001; insulin: 115,8 ± 22.1 vs 40.7 ± 7 pmol/L , 
p=0.0012).
During the oral glucose tolerance test, blood glucose and insulin levels rose to values 
significantly higher in obese patients in comparison to the healthy volunteer group (Fig. 8A, 
B). In controls, plasma 26RFa concentrations were stable during the first 90 min of the test 
and increased significantly at 120 min (p<0.05; Fig. 8C). By contrast, there was not 
significant alteration of the plasma 26RFa concentrations all along the test in obese patients 
(Fig. 8C). In addition, it is to note that, during the test, 26RFa blood levels were significantly 
higher in the obese patients (p<0.05; Fig. 8C), as assessed by the AUC analysis (Fig. 8D). 
Correlation analysis revealed that AUC of plasma 26RFA concentrations were positively 
correlated with BMI (Fig. 9A), fasting insulinemia (Fig. 9B) and with a marker of insulin 
resistance represented by the HOMA R index (Fig. 9C). Moreover, markers of insulin 
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secretion such as HOMA B and insulinogenic index were also strongly correlated with the 
26RFa  AUC (Fig. 9D, E).
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 DISCUSSION
The neuropeptide 26RFa and its receptor GPR103 have been discovered simultaneously by 
us, and two pharmaceutical groups in 2003 (9-11). Animal studies accumulated during the last 
decade have revealed that, centrally, this neuropeptidergic system plays a key role in the 
control of feeding behavior (12), and that, at the periphery, it is involved in the regulation of 
glucose homeostasis (13). However, our knowledge on the 26RFa/GPR103 system in human 
is far more limited. In the present study, we took advantage of a collaboration with different 
Departments of the University Hospital to obtain human tissue and plasma samples to 
investigate the 26RFa/GPR103 system in human with regard to its implication in the 
peripheral regulation of glucose homeostasis.
The availability of various human tissue sections gave us the opportunity to decipher the 
distribution and localization of 26RFa and GPR103 in the gut and the pancreas. Our 
observations indicate that 26RFa is present all along the gastro-intestinal tract, from the 
stomach to the colon. However, the neuropeptide is much more abundant in the stomach and 
duodenum than in the ileum and the colon confirming preliminary data obtained previously by 
our team (24). The high expression of 26RFa in the stomach is very interesting. Indeed, 
26RFa strongly stimulates food intake when injected centrally by modulating the NPY/POMC 
system of the Arc (18, 30). The stomach is well known to produce another important 
orexigenic peptide that is ghrelin (31, 32). Ghrelin is secreted by the endocrine cells of the 
stomach in the general circulation during the preprandrial period to initiate food intake by 
targeting the NPY neurons of the Arc that express the ghrelin receptor, GHSR (33). The NPY 
neurons have been previously shown to express GPR103, the 26RFa receptor, and to mediate 
the orexigenic activity of 26RFa (18). Our team has shown that, in human, high levels of 
26RFa are detected in the blood (24, present study), and that the neuropeptide is able to cross 
the brain-blood-barrier in rats (unpublished data). Together, these observations suggest that 
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26RFa, in as much as ghrelin, may be released by the stomach into the blood and cross the 
brain-blood-barrier to target the NPY neurons of the Arc to exert its orexigneic activity. In 
addition, it also raises the exciting hypothesis that the stomach is a major source of orexigenic 
peptides that trigger the initiation of food intake. However, we observed that 26RFa is present 
in abundance in the parietal cells whereas ghrelin is specifically produced by the endocrine 
cells, suggesting that the two orexigenic peptides are produced by distinct cells of the stomach 
gastric glands.
The present study also reveals that 26RFa is present in a number of enterocytes and goblet 
cells in the human duodenum. In mice, we have previously shown that 26RFa is highly 
expressed by the enterocytes of the duodenum that release the peptide into the blood after an 
oral glucose load, leading to the incretin effect of 26RFa (24). We show here that, in healthy 
volunteers, plasma 26RFa levels are increased 90 min after an oral glucose load, suggesting 
that, in human as observed in mice, duodenal 26RFa may be secreted by the gut after a 
glucose ingestion.
Our histological observations also reveal a high expression of the 26RFa receptor all along 
the gastro-intestinal tract, notably in the stomach and the duodenum. In fact, in the gut, 
GPR103 exhibits a cell localization and distribution very similar to that of its ligand, 
suggesting that 26RFa may act in the gastro-intestinal tract via an autocrine mechanism. The 
presence of GPR103 in the gastric glands and the enterocytes and goblet cells suggests an 
involvement of the 26RFa/GPR103 system in the secreting activity of the gut although to our 
knowledge such an activity of this peptidergic system has never been reported. However, it is 
to note that the role of various peptides/hormones of the gut such as cholecystokinin, secretin, 
GIP, VIP, in the secretion of gastrin, pepsin, HCl is clearly established and widely 
documented (34), and that some of them such as cholecystokinin, GIP or secretin are also 
involved in the control of feeding behavior and glucose homeostasis. Collectively, these 
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observations support the idea that 26RFa is a gut hormone able to modulate gut functions and 
regulate energy and glucose metabolism. 
In the pancreas, we found that 26RFa and its receptor are strictly localized in the pancreatic 
islets. In addition, double labeling experiments reveal that the 26RFa/GPR103 system is 
mainly expressed by the β cells that produce and secrete insulin, suggesting a role of this 
peptidergic system in the production and secretion of insulin. Consistent with this hypothesis, 
previous studies performed in mice have shown that 26RFa can directly stimulate insulin 
secretion by the β cells by activating GPR103, which is expressed by the same cells (24). It is 
thus probable that, in human, 26RFa displays the same insulin-secreting activity than that 
observed in mice. In addition, the presence of 26RFa, together with GPR103, in the β cells 
suggests that the peptide may regulate insulin secretion via an autocrine mechanism. Finally, 
26RFa has also been shown to prevent cell death and apoptosis induced by serum starvation, 
cytokine synergism and glucolipotoxicity in a model of isolated human pancreatic islets (23). 
This latter observation indicates that, in addition to its insulinotropic action, the 
26RFa/GPR103 system is able to promote survival of β cells. The present double labeling 
experiments also reveal that both 26RFa and GPR103 are expressed in non insulin-producing 
cells in the pancreatic islets that may correspond to glucagon- and somatostatin-producing 
cells, suggesting a role of the peptidergic system in the metabolism and/or secreting activity 
of the α and δ cells. A single study, using perfused rat pancreas, report that infusion of 26RFa 
has no effect on glucagon output (35). Therefore, the role of the 26RFa/GPR103 system in the 
glucagon and somatostin cells deserves further investigation.
In addition to the above data that precisely determined the location of the system 
26RFa/GPR103 in the gastro-intestinal tract, we thought it was important to examine the role 
of this peptidergic system in the regulation of glucose homeostasis. In fact, previous 
experiments performed in mice by our team have led to the conclusion that 26RFa regulates 
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glucose homeostasis by acting as an incretin, and that the global anti-hyperglyceminc effect of 
the peptide was due to an increase of insulin secretion associated with an enhanced insulin 
sensitivity (24). In the present work, we have evaluated plasma 26RFa concentrations in 
healthy volunteers and in obese patients during an oral glucose tolerance test. We found that 
26RFa blood levels are significantly higher in the obese patients as compared to the healthy 
volunteers, and that the 26RFa secretion kinetics are different in the two groups during the 
glucose load. This result is in agreement and complete previous data reporting a significant 
increase of fasting plasma 26RFa concentrations in obese subjects and obese diabetic patients 
(24), raising the hypothesis that this up-regulation of the 26RFa system may play a role in the 
development and maintenance of the obese status. We may also speculate that the rise of 
plasma 26RFa observed in the obese patients is due to a loss of effect of 26RFa on the 
regulation of glucose homeostasis. Indeed, we have recently found that, in high fat-induced 
obese mice, the antihyperglycemic effect exerted by 26RFa is totally vanished, due to a total 
loss of effect of the peptide on insulin secretion and a strongly diminished effect on insulin 
sensitivity (36). In addition, we observed that this loss of effect of 26RFa in the regulation of 
glycemia is associated with a decreased expression of GPR103 in insulin target organs and 
pancreatic islets. Consequently, we hypothesize that the increase of 26RFa production could 
reflect the implementation of a compensatory mechanism to counterbalance the low 
expression levels of GPR103 induced by the high fat diet. Further analysis of GPR103 
expression in human adipose tissue and muscle obtained from both healthy controls and obese 
patients is needed to confirm this hypothesis.
In addition, we found strong positive correlations between 26RFa blood levels and the 
BMI, and with various parameters of insulin secretion and insulin resistance. These findings 
are in agreement with previous data obtained from a large cohort of subjects including healthy 
controls, obese, diabetic and obese diabetic patients, revealing that fasting 26RFa blood 
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concentrations were correlated with BMI and fasting insulinemia (24). The strong correlation 
between the 26RFA OGGT AUC and fasting insulinemia or HOMAR index suggests that the 
26RFa peptidergic system may be implicated in the occurrence of the decreased insulin 
sensitivity and increased insulin resistance observed in a number obese patients. Studies are 
planed in a near future to determine the role of the 26RFa/GPR103 on the insulin signaling 
pathway.
In conclusion, the present histological and physiological data obtained in human reveal that 
the 26RFa/GPR103 peptidergic system is abundantly expressed in the gut and the pancreas 
and suggest an involvement of this peptidergic system in the control of human glucose 
homeostasis.
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LEGENDS TO FIGURES
Figure 1. Distribution of 26RFa-like immunoreactivity in the human stomach. (A, B) Low 
magnification photomicrographs showing a dense immunolabeling in the gastric glands. (C, 
D) Higher magnification photomicrographs reveal that, in the surface epithelium cells, the 
immunostaining is restricted to the basal pole of the cells (C). In the neck part of the gastric 
glands, 26RFa-positive cells are large and exhibit a round shape identifying them therefore as 
parietal cells (D). (E, F) Control sections showing that preincubation of the 26RFa antibodies 
with synthetic human 26RFa (10-6 M) (E) or substitution of the primary antibodies with Tris 
buffer saline (F) results in a total loss of the immunostaining. Scale bars: (A, B), 200 µm; (E, 
F), 50 µm; (D), 25 µm; (C), 10 µm.
Figure 2. Distribution of GPR103-like immunoreactivity in the human stomach. (A) Low 
magnification photomicrograph showing a dense immunolabeling in the gastric glands. (B-D) 
Higher magnification photomicrographs reveal that, in the surface epithelium cells, the 
immunostaining for the 26RFa receptor is restricted to the basal pole of the cells (B, C). In the 
neck part of the gastric glands, GPR103-positive cells are large and exhibit a round shape 
identifying them therefore as parietal cells (D). (E, F) Control sections showing that 
substitution of the GPR103 primary antibodies with Tris buffer saline results in a total loss of 
the immunostaining. Scale bars: (A), 200 µm; (E, F), 50 µm; (B, D), 25 µm; (C), 10 µm.
Figure 3. Distribution of 26RFa- and GPR103-like immunoreactivity in the human 
duodenum. (A-D) Photomicrographs showing that some villosities are abundantly labeled 
with the 26RFa antibodies (A, C), whereas others are totally unstained (B, C). High 
magnification indicates that the enterocytes as well as the goblet cells display intense 26RFa-
like immunoractivity (D). (E-H) Low magnification photomicrographs showing that, in the 
duodenal villosities, the immunolabeling for the 26RFa receptor is less important than for 
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26RFa (E, F). Higher magnification photomicrographs reveal that, in some cases, GPR103-
like immunoreactivity is concentrated in the basal pole of the enterocytes and the goblet cells 
(G), whereas, in other cases, the labeling is homogeneously distributed throughout the 
cytoplasm of the cells (H). Scale bars: (A, B, E), 200 µm; (F), 50 µm; (C, G), 25 µm; (D, H), 
10 µm.
Figure 4. Distribution of 26RFa- and GPR103-like immunoreactivity in the human ileum and 
colon. (A, B) In the ileum, 26RFa-immunolabeling is present in scattered enterocytes and 
goblet cells of the villosities (A). A higher magnification photomicrograph shows that a 
number of villosities are, indeed, devoid of immunostaining (B). (C, D) Similarly, GPR103-
immunolabeling is present in a few enterocytes and goblet cells of the ileum (C), but when the 
cells are labeled, the immunostaining is intense (D). (E, F) In the colon, most of the villosities 
are devoid of 26RFa-immunolabeling (E). However, in some cases, weakly immunostained 
enterocytes can be found (F). (G, H) Disribution and localization of the 26RFa receptor in the 
colon is very similar to that observed in the ileum with an intense immunostaining in the 
enterocytes and goblet cells of some villosities.  Scale bars: (A, C, E, G), 200 µm; (B), 50 µm; 
(F, H), 25 µm; (D), 10 µm.
Figure 5. Distribution of 26RFa-like immunoreactivity in the human pancreas. (A, B) Low 
magnification photomicrograph showing that the 26RFa labeling is present in the endocrine 
islets, whereas the exocrine tissue is virtually devoid of 26RFa-like immunoreactivity (A). A 
higher magnification reveals that almost all the cells of the islet are strongly labeled with the 
26RFa antibodies (B). (C, D) Similarly, the pancreatic islets are strongly labeled with the 
GPR103 antibodies (C). However, a higher magnification of the islets reveals that some islet 
cells are strongly labeled (arrows) whereas others are devoid of immunostaining (arrowheads) 
(D). (E, F) Photomicrographs showing that preincubation of the 26RFa antibodies with 
synthetic human 26RFa (10-6 M) results in a total loss of the immunostaining in the pancreatic 
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islets (F). (G, H) Similarly, substitution of the GPR103 antibodies with Tris buffer results in a 
total loss of the immunostaining in the pancreatic islets (H). Scale bars: (E-H), 200 µm; (A, 
C), 50 µm; (B, D), 10 µm.
Figure 6. Co-distribution of 26RFa-like immunoreactivity (LI) with insulin, glucagon and 
somatostatin in the human pancreas. (A, B) Consecutive sections treated with the 26RFa 
antibodies or the insulin antibodies showing that the histological distribution of 26RFa-LI (A) 
is similar to that of insulin (B). (C) Double immunolabeling experiment with the 26RFa and 
the insulin antibodies shows a colocalization of the neuropeptide and the hormone in most of 
the pancreatic islet cells (small arrowhead in the merge photomicrograph for instance). 
However, some cells are only labeled with the 26RFa antibodies (arrows), whereas others 
only exhibit insulin-like immunoreactivity (large arrowhead). (D, E) Consecutive sections 
treated with the 26RFa antibodies and glucagon antibodies suggesting that in some cases 
glucagon-positive cells (arrow) (E) display 26RFa-like immunoreactivity (arrow) (D). (F, G) 
Consecutive sections treated with the 26RFa antibodies and somatostatin antibodies 
suggesting that in some cases somatostatin-positive cells (arrow) (G) display 26RFa-like 
immunoreactivity (arrow) (F). Scale bars: (A, B, D-G), 25 µm; (C), 50 µm.
Figure 7. Co-distribution of GPR103-like immunoreactivity (LI) with insulin, glucagon and 
somatostatin in the human pancreas. (A, B) Consecutive sections treated with the GPR103 
antibodies and insulin antibodies reveal that the histological distribution of GPR103-LI (A) is 
closely related to that of insulin (B). (C, D) Consecutive sections treated with the GPR103 
antibodies and glucagon antibodies suggesting that, in some cases, glucagon-positive cells 
(arrow) (D) display GPR103-like immunoreactivity (arrow) (C). (E, F) Consecutive sections 
treated with the GPR103 antibodies and somatostatin antibodies suggesting that, in some 
cases, somatostatin-positive cells (arrow) (F) display 26RFa-like immunoreactivity (arrow) 
(E). Scale bars: 25 µm.
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Figure 8. Plasma profiles of glucose, insulin and 26RFa during an oral glucose tolerance test 
in healthy volunteers and obese patients. (A, B) As expected, in obese patients (n=8), blood 
glucose (A) and insulin (B) levels rose to values significantly higher to those measured in 
healthy volunteers (n=9). (C, D) Plasma 26RFa concentrations in the healthy volunteers are 
stable during the first 90 min of the glucose tolerance test and significantly increase at 120 
min (C). By contrast, there is no significant alteration of the plasma 26RFa concentrations all 
along the test in the obese patients (C). However, it is to note that, during the test, 26RFa 
blood levels are significantly higher in the obese patients as assessed by the AUC analysis 
(D). *, p<0.05; **p<0.01 obese patients vs healthy volunteers. #, p<0.05 T120 vs T90 in 
healthy volunteers.
Figure 9. Correlation analysis of the AUC of plasma 26RFA concentrations during the oral 
glucose tolerance test with various glycemic and metabolic parameters. Plasma 26RFA AUC 
is positively correlated with BMI (A), fasting insulinemia (B) and with the marker of insulin 
resistance, the HOMA R index (C). Moreover, markers of insulin secretion such as HOMA B 
and insulinogenic index are also strongly correlated with the 26RFa AUC (D, E).
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